

Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

BAYER AKTIENGESELLSCHAFT

Form 6-K

January 29, 2003

=====

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----

FORM 6-K

Report of Foreign Issuer  
Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of January, 2003

-----

Bayer Aktiengesellschaft  
(Exact name of registrant as specified in its charter)

Bayerwerk, Gebaude W1  
D-51368 Leverkusen  
Germany  
(Address of principal executive offices)

-----

Indicate by check mark whether the registrant files or will file annual  
reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

---  
Indicate by check mark whether the registrant by furnishing information  
contained in this Form is also thereby furnishing information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes      No    X  
---      ---

If "Yes" is marked, indicate below the file number assigned to the  
registrant in connection with Rule 12g3-2(b): 82- N/A

EXHIBIT INDEX

1. Press release dated September 18, 2002
2. Press release dated September 24, 2002
3. Press release dated October 1, 2002

## Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

4. Press release dated October 1, 2002
5. Press release dated October 4, 2002
6. Press release dated October 8, 2002
7. Press release dated October 16, 2002
8. Press release dated October 28, 2002
9. Press release dated October 28, 2002
10. Press release dated October 28, 2002
11. Press release dated October 29, 2002
12. Press release and Third Quarter 2002 Consensus Estimates, November 6, 2002
13. Press release dated November 12, 2002
14. Stockholders' Newsletter and Interim Report for the First Three Quarters, November 12, 2002
15. Press release dated November 22, 2002
16. Press release dated December 5, 2002
17. Press release dated December 5, 2002
18. Press release dated December 6, 2002
19. Press release dated December 16, 2002
20. Press release dated December 20, 2002
21. 2003 Calendar of Investor Relations Events

### EXHIBIT 1

Bayer CropScience agrees to sell wheat herbicide to Arvesta Corporation  
-----

Monheim - Bayer CropScience has agreed to divest its wheat herbicide Everest (R) to San Francisco-based Arvesta Corporation, pending approval by the U.S. and Canadian regulatory authorities. Terms of the purchase agreement were not disclosed.

The sale of Everest (R) is part of the requirements to which Bayer CropScience agreed with the U.S. Federal Trade Commission and the Canadian Competition Bureau as a condition of approval for Bayer to acquire Aventis CropScience.

Registered since October 2000, Everest (R) is a selective post-emergence grass herbicide for early season control of wild oats, green foxtail and other grasses in winter and spring wheat crops. Everest (R) provides growers with a rotational tool to manage resistance and is currently sold primarily in Canada and the United States.

## Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

"The negotiations with Arvesta were concluded in a professional and expeditious manner and I am very pleased with the results" stated Jochen Wulff, Chairman of the Board of Bayer CropScience.

"In the two years since Everest (R) was introduced to the market by Bayer, it fulfilled our expectations", added Emil Lansu, Head of the NAFTA-region for Bayer CropScience. "The pending purchase by Arvesta will ensure that this innovative herbicide remains available to the Canadian and US growers who have come to value it."

Bayer CropScience, a subsidiary of Bayer AG with annual sales of some Euro 6.5 billion, is one of the world's leading innovative crop science companies in the areas of crop protection, seeds and green biotechnology, as well as non-agricultural pest control. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications.

Bayer CropScience has a global workforce of 22,000 and is represented in 122 countries, ensuring proximity to dealers and consumers.

Leverkusen, September 18, 2002

### Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

## EXHIBIT 2

10th World Congress of the International Society for Sexual and Impotence Research (ISSIR):  
Men Treated with Vardenafil Report Reliable Improvement in Erectile Function over Time and Improvements in Erection Quality Following Prostate Cancer Surgery

Leverkusen - Findings from a clinical trial investigating the efficacy of Vardenafil will be presented at the 10th World Congress of the International Society for Sexual and Impotence Research (ISSIR) in Montreal. Men with erectile dysfunction (ED) who were taking the oral investigational drug Vardenafil reported consistently improved erectile function (EF) the first time they took the drug and subsequently thereafter. For the three months of the study involving over 800 ED patients, Vardenafil was reported to consistently improve rates of successful penetration, intercourse success and overall satisfaction during the first and subsequent attempts. Investigators evaluated the ability of Vardenafil to provide reliable efficacy over time in a broad population of men with ED. They analysed data from a phase III, randomised, double-blind study in which 805 men with ED received Vardenafil 5, 10 or 20 mg or placebo for up to 26 weeks. The analysis showed that at a 20 mg dose:

- o On average men were successful in 74 percent of their first attempts in penetrating their partner compared with 46 percent of men taking placebo.
- o Of those men taking Vardenafil who were successful the first time, they

## Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

continued to achieve successful penetration in 91 percent of subsequent attempts.

"Men want to be confident that the ED drug they are taking works the first time and time after time," said Luc Valiquette, M.D., Professor of Urology at the Hospital Saint-Luc du CHUM in Montreal. "I've seen frustration in some of my patients because some of the current treatments do not consistently work, and their efficacy may diminish over time. This reinforces the need for new ED therapies that are effective, consistent and safe."

Data from two other clinical trials presented at the ISSIR meeting also showed that over time men taking Vardenafil consistently report improvement in EF.

- o In a year-long study of Vardenafil, a broad population of men with ED reported improvement in their EF.

- o A six-month open label study of Vardenafil reported return to normal EF, with 81 percent of men reporting improved erections.

In another study, the first of its kind to assess the effect of a phosphodiesterase (PDE-5) inhibitor on EF and depressive symptoms among men with ED resulting from prostate cancer surgery, men taking Vardenafil were more likely to report improved erections and fewer depressive symptoms than men taking placebo.

In this phase III clinical trial, 440 men aged 44 to 77 years with ED following prostatectomy and who experienced ED for six months before entering the study, were randomly assigned to placebo or Vardenafil (at a dose of 10 or 20 mg) for 12 weeks. After 12 weeks:

- o Up to 71 percent of patients who had undergone a specific type of prostatectomy, known as bilateral nerve-sparing, reported statistically significant improvement in erections with Vardenafil 20 mg versus 12 percent of men taking placebo.

- o A significant decrease in depressive symptoms was observed among a small subset of depressive prostatectomy patients taking Vardenafil 20 mg.

"Men who suffer from ED following prostatectomy are among the most difficult to treat because their ED is typically severe. The finding that Vardenafil significantly improved erectile function in our study patients is important because more than two thirds of these men had severe ED," said Gerald Brock, M.D., lead study investigator and Associate Professor, Department of Surgery, Division of Urology at St. Joseph's Health Centre in London, Ontario, Canada. He also added: "The finding that Vardenafil eased depressive symptoms in these men is very good news, because it means that Vardenafil helps improve quality of life in men who are often suffering both emotionally and physically from this condition."

In all these studies, drug-related adverse events were reported as generally mild to moderate in intensity with the most frequent adverse events being headache, flushing and rhinitis. ED - the persistent inability to attain and maintain an erection adequate to permit satisfactory sexual intercourse - is a common health condition among men that is largely untreated. It is estimated that some degree of ED affects more than one half of all men over the age of 40 and that worldwide an estimated 152 million men suffer from ED.

Vardenafil, researched and discovered by Bayer AG, will be marketed by Bayer and GlaxoSmithKline (GSK) through a worldwide co-promotion and co-development

## Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

agreement that the two companies signed in November 2001. Marketing Authorisation Applications have been approved by regulatory authorities in several Latin American countries and have been submitted for regulatory review in all major regions worldwide, including the United States, Europe and Japan.

Bayer is an international, research-based group with major businesses in healthcare, agriculture, polymers and specialty chemicals.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Leverkusen, 2002-09-024

### Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

### EXHIBIT 3

Bayer CropScience becomes first legally independent subgroup  
Bayer Group CEO Werner Wenning: "A milestone in our reorganization"

Leverkusen - The Bayer Group has taken a major step forward in its reorganization program: Bayer CropScience becomes the first legally independent operating subgroup upon its entry in the trade register on October 1, 2002. The new company - created by combining Bayer's former Crop Protection Business Group with the activities of Aventis CropScience, which Bayer acquired in early June 2002 - is the world's number two agrochem supplier with about 22,000 employees and some EUR 6.5 billion in sales. "We have now reached an important milestone in the reorganization of the Bayer Group into four operating subsidiaries and three service companies under the umbrella of a management holding company," said Werner Wenning, Chairman of the Board of Management of Bayer AG. "In the short time since the decision was made in September 2001 to form an independent crop protection subsidiary, excellent work has been done, and done quickly - on top of the obvious necessity of looking after our day-to-day operations."

According to Wenning, Bayer CropScience has a number of advantages as a new corporate entity. For example, it is an agile unit that can operate flexibly and independently in the market, and its creation has greatly facilitated the integration of Aventis CropScience. Wenning said that the experience gained by Bayer CropScience along its path to legal independence is also benefiting the other three future operating subgroups - Bayer Chemicals, Bayer HealthCare and Bayer Polymers - and the service companies Bayer Business Services, Bayer Technology Services and Bayer Industry Services. Pending the approval of the Annual Stockholders' Meeting in April 2003, these companies are scheduled to become legally independent thereafter during the course of the year.

"We have created a modern company that aims to fully exploit its strengths in crop protection, the seed business and biotechnology, as well as in

## Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

nonagricultural pest control, for the benefit of its customers," explained Dr. Jochen Wulff, Management Board Chairman of Bayer CropScience AG. "With an innovative and research-oriented focus, we intend to grow considerably faster than the market and thus to increase our sales to more than EUR 7 billion over the next three to four years."

Following the successful integration of Aventis CropScience, the company aims to achieve a return on sales of 20 percent by 2006, said Wulff. Estimated one-time integration charges of EUR 500 million are offset by a similar volume of synergies expected to be fully realized as of 2005.

Leverkusen, October 1, 2002

### Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

### EXHIBIT 4

Bayer Biological Products Receives FDA Approval for Additional Kogenate(R) FS Manufacturing Processes  
Approval of 200 liter fermenters increases production capacity for the U.S.

Leverkusen - Bayer Biological Products (BP) announced today receipt of United States Food and Drug Administration (FDA) approval for additional processes used in the manufacture of Kogenate(R) FS, Antihemophilic Factor (Recombinant), formulated with sucrose. This approval enables Bayer BP to expand production capacity and reinforces its position as a reliable supplier of Kogenate(R) FS. Further, the approval creates additional momentum for Bayer BP to achieve its highest ever quarterly releases of recombinant factor VIII by spring 2003.

Specifically, FDA approved Bayer BP's use of six 200 liter fermenters at its Berkeley Calif. manufacturing facility. The 200 liter fermenters, twice the volume of the fermenters currently utilized, are used to grow hamster kidney cells that have been modified through highly advanced recombinant technology to produce human Factor VIII, the blood protein missing in individuals living with hemophilia A.

Because the 200 liter fermenters are now approved in the United States, Kogenate(R) FS manufactured using these fermenters can be released for use in the U.S. marketplace.

Dr. Glenn Pierce, president of the National Hemophilia Organization, expressed his excitement over the approval. "Over the last several months Bayer BP has worked extremely hard to get back to normal releases of recombinant Factor VIII in a marketplace that has experienced significant shortages. This latest approval of their 200 liter fermenters is very good news for the hemophilia community."

Dr. Gunnar Riemann, executive vice president, Bayer Corporation, and president,

## Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

Bayer BP Division, commented on the significance of the approval. "Our commitment to providing reliable supplies of Kogenate(R) FS is stronger than ever, and our releases are continuing to increase. This approval is one of several positive communications received recently from FDA, and is extremely important to us and to the community of patients we serve." These recently received positive communications relate to inspections conducted over the last two years at the Clayton, North Carolina and Berkeley manufacturing facilities. In these communications, FDA expressed its satisfaction with Bayer BP's responses and progress made to address observations made during inspections at Berkeley and Clayton in late 2000, a subsequent Clayton inspection in March 2001, and in the Warning Letter issued July 2001. As a result, the Warning Letter is now officially closed. Additionally, FDA informed Bayer BP that responses and corrective actions following the March 2002 Berkeley inspection are acceptable. These communications reinforce findings of compliance by Canadian and European regulatory authorities following their inspections earlier this year.

Reacting to the recent positive news from FDA, Carol Moore, vice-president of regulatory affairs at Bayer BP stated, "Needless to say, we are very pleased with the approval of the 200 liter fermenters and the closing of the Warning Letter. Sustainable compliance with FDA's Good Manufacturing Practice standards, will always be our goal and we will meet that goal through continuous vigilance, evaluation, and change as warranted."

Leverkusen, 2002-10-01

### Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

### EXHIBIT 5

Bayer plans to sell Rhein Chemie to Advent International  
Transfer scheduled for November 2002

Leverkusen - Bayer AG intends to sell its subsidiary Rhein Chemie Rheinau GmbH, Mannheim, Germany, to a group of financial investors advised by Advent International Corporation, Boston, for EUR 215 million, including the assumption of debt. The transaction would include the wholly owned subsidiary iSL-Chemie GmbH & Co. KG of Kurten, Germany, as well as Rhein Chemie affiliates in the United States and Japan and a Chinese joint venture in which Rhein Chemie owns a 90 percent interest. It is planned to complete the sale at the beginning of November, subject to the approval of the relevant antitrust authorities.

"Under this new ownership, Rhein Chemie would have excellent prospects of further expanding its strong market position," commented Bayer AG Management Board Chairman Werner Wenning. In December 2001, Bayer announced its intention to divest Rhein Chemie and other subsidiaries so as to focus more closely on its

## Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

core businesses. The sale of Holzminden, Germany-based subsidiary Haarmann & Reimer to the financial investor EQT was completed only a few days ago.

Founded in 1889, Rhein Chemie has been a subsidiary of Bayer AG since 1971. The company is an internationally successful supplier of specialties to the rubber, lubricant and plastic industries. Its 1,100 employees in Germany and around the world, including 550 in Mannheim, generated global sales in 2001 of approximately EUR 320 million. Rhein Chemie operates production facilities in Germany, the United States, China, Japan and other countries. With more than 50 investments worldwide in the chemical and pharmaceutical industry, Advent International Corporation has extensive experience in this sector. Its investments in European companies include Vinnolit in Germany, Materis in France and Pemco in Belgium.

Advent International is one of the world's largest private equity firms with EUR 6 billion under management and offices in 14 countries. The company employs more than 100 experts in the United States, Europe, Latin America and Asia. Since its founding in 1984, Advent International has invested in over 500 companies. The chemical and pharmaceutical sector is one of Advent International's main fields of expertise in Europe.

Leverkusen, October 4, 2002

### Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

## EXHIBIT 6

### Relaunch of the Bayer AG Investor Relations website

Leverkusen - Bayer AG Investor Relations has offered an information platform for private and institutional investors and analysts at [www.investor.bayer.com](http://www.investor.bayer.com) since 1998. In view of the increasing importance of the Internet medium for the financial community, we have redesigned our website to make it more user-friendly, at the same time increasing the amount of information offered and introducing new functionalities.

- o Under Downloads you will find documents dating from 1998 to the present day for download.

- o Under Investor Handout, the "Handout Highlights" present the most important information in a nutshell. "My Handout" enables you to create your own personal handout by selecting the documents you need. The "Slideshow" allows convenient viewing.

- o The My Documents function offers the collection and combined download of documents as a ZIP file.

Visit us at



## Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

www.investor.bayer.com (English) or

www.investor.bayer.de (German)

Leverkusen, October 8, 2002

Sincerely,  
Your Bayer AG Investor Relations team

The relaunch was designed and implemented in cooperation with antwerpes & partner ag, Cologne.

### EXHIBIT 7

Sale of Bayer's household insecticides business  
Bayer and SC Johnson have signed Letter of Intent

Leverkusen - Bayer AG and SC Johnson have signed a letter of intent with regard to the sale of Bayer AG's household insecticides business. Bayer aims to complete the sale by the end of 2002. Comprising mainly the successful Baygon(R) insecticide and Autan(R) repellent brands, which hold leading positions in their market segments, the business has annual sales of some EUR 400 million.

In March 2002 Bayer AG announced that the household insecticides business would be sold to enable its Consumer Care Business Group to concentrate on its business in non-prescription health care products.

Leverkusen, October 16, 2002

#### Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

### EXHIBIT 8

Bayer CropScience AG to sell a range of products to BASF  
Company on track with regulatory divestments subsequent to acquisition of Aventis CropScience

Monheim - Bayer CropScience AG today announced that it intends to sell a package of selected insecticides and fungicides to BASF AG while retaining certain back-licenses for non-agricultural applications. The total package is valued at EUR 1,330 million. Taking into consideration the back-licenses the cash purchase price amounts to EUR 1,185 million. With the completion of the envisaged

## Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

transaction, Bayer CropScience would fulfill within the given timeframe a major condition imposed by the European Commission and the U.S. Federal Trade Commission (FTC) as part of the Aventis CropScience acquisition. This transaction is subject to the approval by the European Commission and the U.S. Federal Trade Commission.

Following the respective consent orders the agreements with BASF contain assets and rights related to two insecticides (active ingredients: Fipronil, Ethiprole) and a number of fungicides (active ingredients: Prochloraz, Iprodione, Triticonazole, Fluquinconazole and Pyrimethanil) for certain regions and application fields. BASF will also acquire the Aventis CropScience manufacturing plant in Elbeuf, France. The total revenue from the products and operations involved in the transaction amounted to about EUR 500 million in 2001.

"After the sale of these products, Bayer CropScience can now focus entirely on developing its business and expanding its market position", said Werner Wenning, Chairman of the Board of Management of Bayer AG. "Cash-in from the sale also contributes to improving the Group